# Nectero Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nectero-medical

- Industry: Biotechnology
- Headquarters: Tempe, US
- Website: www.necteromedical.com
- Total disclosed funding: $52M
- Latest round: Series D (Apr 4, 2024)
- Investors on record: 6

## About

Founded in 2017 and based in Arizona, US,  Nectero Medical, Inc. operates as a biotechnology company developing a minimally invasive treatment for small- to mid-sized AAAs. In April 2024, Nectero Medical Inc. raised USD 96 million in Series D funding led by Norwest Venture Partners, Boston Scientific Corporation, BioStar Capital, Cadence Healthcare Ventures, and Aphelion Capital. The Series D funding values Nectero Medical Inc. at USD 139.81 million post-money. As of 2024, the company is led by its president and CEO, Jack Springer.

Nectero Medical is a clinical-stage biotech platform that develops novel therapies for patients with infrarenal abdominal aortic aneurysms (AAAs). The company provides an investigational treatment called Nectero Endovascular Aneurysm Stabilization Treatment (Nectero EAST®) System, a single-use, endovascular system that targets abdominal aortic aneurysms (AAA), specifically small- to mid-sized ones (maximum diameter 3.5–5 cm).

The company plans to use the funds raised in April 2024 to conduct Phase II and III trials and submit a new drug application to the U.S. Food and Drug Administration.

## Funding rounds

- Series D, Apr 4, 2024, $33M — Norwest Venture Partners, BioStar Capital, Aphelion Capital, Boston Scientific Corporation, Cadence Healthcare Ventures
- Series C, Aug 16, 2021, $20M — Boston Scientific Ventures

## Investors

- Boston Scientific Ventures (https://capitalatlas.ai/funds/boston-scientific-ventures) — Series C
- Norwest Venture Partners (https://capitalatlas.ai/funds/norwest-venture-partners) — Series D
- BioStar Capital (https://capitalatlas.ai/funds/biostar-capital) — Series D
- Aphelion Capital (https://capitalatlas.ai/funds/aphelion-capital) — Series D
- Boston Scientific Corporation — Series D
- Cadence Healthcare Ventures — Series D